^
    19h
    Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib. (PubMed, NPJ Precis Oncol)
    Among the three paradigms, MET-specific monitoring provided the most favorable diagnostic performance to identify long-term responders, with a specificity of 90% and a positive predictive value of 80%. These data demonstrate that early MET-specific ctDNA clearance is a robust on-treatment biomarker for ensartinib benefit in METex14 NSCLC, while broader ctDNA profiling remains valuable for uncovering emerging resistance mechanisms.
    Journal • Circulating tumor DNA
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    Ensacove (ensartinib)
    19h
    Treating Patients With Melanoma and ALK Alterations With Ensartinib (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
    |
    BRAF V600 • ALK fusion • ALK mutation
    |
    Ensacove (ensartinib)
    2d
    Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis. (PubMed, Front Oncol)
    Specifically, lorlatinib demonstrated superior efficacy in the Non-Asian subgroup (86.8%), patients without brain metastasis (84.7%), those with Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1 (78.5%), males (71.2%), females (83.9%), patients aged < 65 years (74.3%), and never-smoking patients (89.7%)...Ensartinib achieved the optimal PFS in the Asian subgroup (71.8%)...Alectinib had the lowest hepatic and gastrointestinal AEs risk, while iruplinalkib had the lowest hematological AEs risk. https://www.crd.york.ac.uk/prospero/, identifier CRD42023495527.
    Retrospective data • Review • Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement
    |
    Alecensa (alectinib) • Lorbrena (lorlatinib) • Ensacove (ensartinib) • Qi Xinke (iruplinalkib)
    2d
    Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China. (PubMed, Lung Cancer Manag)
    Limited CIR beyond 12 months existed for brigatinib and ensartinib. Results from the Asian group's CIR aligned with global trials. Due to lower BM CIR, lorlatinib showed higher BM management cost savings compared to crizotinib and alectinib in Chinese 1 L patients.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Xalkori (crizotinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Alunbrig (brigatinib) • Ensacove (ensartinib)
    6d
    Exploratory clinical study on preserving organs in patients with stage II-III non-small cell lung cancer(The Future Star) (ChiCTR2500115167)
    P4, N=598, Recruiting, Jiangsu Cancer Hospital; Jiangsu Cancer Hospital
    New P4 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • EGFR L858R • EGFR T790M • ALK mutation
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Ensacove (ensartinib) • Ameile (aumolertinib) • AiRuiLi (adebrelimab)
    6d
    A single-arm, multicenter clinical study of ensartinib combined with chemotherapy as neoadjuvant therapy for ALK-positive non-small cell lung cancer (NSCLC) (TD-ENSEMBLE study) (ChiCTR2500113689)
    P4, N=20, Not yet recruiting, The Second Affiliated Hospital of Air Force Medical University; The Second Affiliated Hospital of Air Force Medical University
    New P4 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion • ALK mutation
    |
    Ensacove (ensartinib)
    6d
    A randomized controlled clinical study on postoperative adjuvant targeted therapy and MRD observation for stage IA non-small cell lung cancer (ChiCTR2500112620)
    P4, N=178, Not yet recruiting, Beijing chest hospital capital medical university; Beijing Chest Hospital Capital Medical University
    New P4 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK fusion • ALK mutation • EGFR positive
    |
    Conmana (icotinib) • Ensacove (ensartinib)
    6d
    A Multicenter, Randomized Controlled Study to Assess the Effects of Ensartinib Versus Placebo Following Chemoradiation in ALK Positive Patients With Stage III Unresectable Non-small Cell Lung Cancer (ChiCTR2500112211)
    P2, N=45, Not yet recruiting, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
    New P2 trial
    |
    ALK fusion
    |
    Ensacove (ensartinib)
    16d
    TD-ENSEMBLE: Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Tang-Du Hospital
    New P1/2 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion • ALK mutation
    |
    carboplatin • Ensacove (ensartinib)
    21d
    Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov)
    P2, N=1376, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Jan 2027
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tibsovo (ivosidenib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)
    1m
    Pulmonary nodules with explosive calcification were finally diagnosed as lung adenocarcinom: A case report. (PubMed, Medicine (Baltimore))
    This case emphasizes that nodules with diffuse, popcorn-like calcification do not rule out the possibility of lung cancer. A comprehensive evaluation integrating multidimensional imaging features is necessary. For nodules with conflicting imaging characteristics, minimally invasive surgical resection remains valuable for diagnosis. This approach broadens our diagnostic perspective on calcified nodules, enhances clinicians' understanding of lung adenocarcinoma, and reduces the rate of misdiagnosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    Ensacove (ensartinib)
    3ms
    Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Shanghai Pulmonary Hospital, Shanghai, China
    New P2 trial
    |
    Ensacove (ensartinib)